- Home
- SBCF vs ARQT Comparison
SBCF vs ARQT Comparison
Compare SBCF & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SBCF | ARQT |
|---|---|---|
| Founded | 1926 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.3B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SBCF | ARQT |
|---|---|---|
| Price | $32.49 | $29.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $31.00 | $24.83 |
| AVG Volume (30 Days) | 862.8K | ★ 1.9M |
| Earning Date | 01-26-2026 | 10-28-2025 |
| Dividend Yield | ★ 2.34% | N/A |
| EPS Growth | ★ 23.57 | N/A |
| EPS | ★ 1.68 | N/A |
| Revenue | ★ $556,541,000.00 | $317,929,000.00 |
| Revenue This Year | $33.11 | $85.51 |
| Revenue Next Year | $30.09 | $30.74 |
| P/E Ratio | $19.32 | ★ N/A |
| Revenue Growth | 12.63 | ★ 129.21 |
| 52 Week Low | $21.36 | $11.13 |
| 52 Week High | $33.23 | $31.77 |
Technical Indicators
Market Signals| Indicator | SBCF | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 57.64 | 56.62 |
| Support Level | $31.48 | $27.55 |
| Resistance Level | $32.81 | $30.26 |
| Average True Range (ATR) | 0.68 | 1.07 |
| MACD | -0.06 | -0.30 |
| Stochastic Oscillator | 57.71 | 45.09 |
Price Performance
Historical ComparisonAbout SBCF Seacoast Banking Corporation of Florida
Seacoast Banking Corp of Florida is a holding company for Seacoast National Bank. The company provides integrated financial services including commercial and consumer banking, wealth management, and mortgage and insurance services to customers across Florida, and through mobile and online banking solutions. In addition, it provides services such as treasury management, brokerage and credit facilities.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.